Physician profile
Matilda E Stephens
NPI 1003999459
$2,299.75
in general payments reported to CMS, 2019-2025
20 companies · $916 in 2025
The $916 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $27.34 · 2023: $616 · 2024: $740 · 2025: $916.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,272.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,272.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $805.02 | 2023-2025 | |
| Novo Nordisk INC | $302.93 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $177.97 | 2022-2025 | Repatha, Repatha, Otezla |
| Exact Sciences Corporation | $157.11 | 2024-2025 | Cologuard Collection Kit |
| Neurelis, INC. | $117.40 | 2023 | Valtoco |
| Itamar Medical INC | $116.79 | 2023 | Watchpatone |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $104.72 | 2024-2025 | Caplyta |
| Axsome Therapeutics, INC. | $68.03 | 2024-2025 | Auvelity |
| Lilly USA, LLC | $53.17 | 2024-2025 | Zepbound, Mounjaro |
| Pfizer INC. | $52.50 | 2022-2025 | |
| Glaxosmithkline, LLC. | $51.38 | 2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Viatris Specialty LLC | $48.81 | 2025 | Yupelri |
| Esperion Therapeutics, INC. | $48.23 | 2023-2025 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.82 | 2024-2025 | Jardiance, Tradjenta |
| Merck Sharp & Dohme LLC | $34.26 | 2025 | Gardasil 9, Capvaxive |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $31.09 | 2025 | Austedo Xr |
| Abiomed | $29.64 | 2025 | |
| Astellas Pharma US INC | $28.95 | 2024 | Veozah |
| Insulet Corporation | $17.69 | 2025 | Omnipod |
| Lundbeck LLC | $14.24 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matilda Stephens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.